A chewing gum developed by AXIM delivers CBD and other crucial cannabinoids
A recent article published in LinkedIn’s Healthcare section on the current U.S. opioid addiction crisis focused on ways doctors themselves are trying to combat the growing epidemic. The article referenced AXIM Biotechnologies as a leader in addressing this crisis (Medical Marijuana Inc. owns approximately 47% of the AXIM common stock).
Taking anti-inflammatory medications used to be the most common way to address chronic pain, while opioids were most commonly used for pain associated with cancer. In the mid-1990s, however, once the FDA approved the long-lasting opioid Oxycontin for reducing pain, everything changed, and, by the turn of the millennium, taking opioids was the most common pain management method.
According to the article, while opioids are effective for temporary pain, long-term use can be highly addictive, despite 1980s reports reporting no long-term addiction issues.
The article referenced AXIM Biotechnologies, headed by medical doctor and dentist Dr. George Anastassov, as one of the leaders in the push to find solutions combating today’s rampant opioid dependency in the U.S. As Dr. Anastassov says, “There is no such thing as addiction to cannabinoids.”
AXIM has developed a chewing gum, CanChew, and is working on other ways to deliver cannabinoids into an individual’s system in hopes of addressing other pain conditions. The article also mentions Dr. Anastassov’s conviction that AXIM Biotechnologies will one day find a way to solve chronic pain.
Read the full article here.
Learn more about Medical Marijuana Inc. and its portfolio of companies, including AXIM Biotechnologies, by reading our news feed.